We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.68%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$2.63B
AUM Growth
+$312M
Cap. Flow
+$315M
Cap. Flow %
11.96%
Top 10 Hldgs %
49.1%
Holding
89
New
29
Increased
24
Reduced
12
Closed
15

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$69M
2
BIIB icon
Biogen
BIIB
+$42.3M
3
AXSM icon
Axsome Therapeutics
AXSM
+$34.6M
4
ALC icon
Alcon
ALC
+$31.7M
5
INSM icon
Insmed
INSM
+$29.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.6M
2
ABBV icon
AbbVie
ABBV
+$72.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$71.9M
4
AZN icon
AstraZeneca
AZN
+$69.4M
5
LLY icon
Eli Lilly
LLY
+$66.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
Nektar Therapeutics
NKTR
$2.39B
$36.7M 1.39%
509,546
+70,916
+16% +$4.04M
AXSM icon
27
Axsome Therapeutics
AXSM
$12.4B
$36M 1.37%
212,747
+200,481
+1,634% +$34.6M
IMTX icon
28
Immatics
IMTX
$1.24B
$35.7M 1.36%
3,630,454
+194,912
+6% +$1.91M
CELC icon
29
PUT
Celcuity
CELC
$4.03B
$34.2M 1.3%
+300,000
New +$32.7M
AXSM icon
30
PUT
Axsome Therapeutics
AXSM
$12.4B
$33.8M 1.28%
+200,000
New +$34.5M
BBIO icon
31
BridgeBio Pharma
BBIO
$16.5B
$30.4M 1.15%
409,183
-311,265
-43% -$22.6M
DYN icon
32
Dyne Therapeutics
DYN
$4.04B
$29.6M 1.13%
1,633,897
-620,264
-28% -$10.7M
INBX icon
33
Inhibrx
INBX
$1.2B
$27.3M 1.04%
406,029
-48,628
-11% -$3.61M
DXCM icon
34
DexCom
DXCM
$27.6B
$24.7M 0.94%
393,576
+15,357
+4% +$1.07M
PHVS icon
35
Pharvaris
PHVS
$2.39B
$23.1M 0.88%
818,328
+73,159
+10% +$1.95M
PFE icon
36
CALL
Pfizer
PFE
$140B
$22.5M 0.85%
+800,000
New +$21.3M
PRAX icon
37
Praxis Precision Medicines
PRAX
$9.07B
$20.5M 0.78%
63,680
-62,042
-49% -$19.2M
GMAB icon
38
Genmab
GMAB
$17.7B
$20.2M 0.77%
+752,261
New +$22.5M
RCUS icon
39
Arcus Biosciences
RCUS
$3.57B
$19.9M 0.76%
923,086
-173,619
-16% -$3.75M
LQDA icon
40
PUT
Liquidia Corp
LQDA
$7.67B
$18.9M 0.72%
+500,000
New +$18.6M
XENE icon
41
Xenon Pharmaceuticals
XENE
$6.32B
$17.7M 0.67%
305,216
+245,316
+410% +$11.3M
SYK icon
42
Stryker
SYK
$127B
$14.6M 0.56%
+44,480
New +$16M
ANAB icon
43
AnaptysBio
ANAB
$1.6B
$13.8M 0.52%
248,253
-39,437
-14% -$2.12M
ROIV icon
44
Roivant Sciences
ROIV
$25.2B
$13.2M 0.5%
477,995
-256,587
-35% -$6.59M
EWTX icon
45
Edgewise Therapeutics
EWTX
$4.39B
$12.2M 0.46%
386,498
-51,321
-12% -$1.48M
CMPX icon
46
Compass Therapeutics
CMPX
$373M
$10.9M 0.41%
2,056,161
-1,309,285
-39% -$7.56M
EXEL icon
47
PUT
Exelixis
EXEL
$13.9B
$10.8M 0.41%
+251,500
New +$10.8M
ORIC icon
48
Oric Pharmaceuticals
ORIC
$1.25B
$8.61M 0.33%
+679,578
New +$7.71M
TNGX icon
49
Tango Therapeutics
TNGX
$4.34B
$8.27M 0.31%
+395,081
New +$5.5M
TYRA icon
50
Tyra Biosciences
TYRA
$1.82B
$7.81M 0.3%
+204,015
New +$6.6M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2026 Portfolio in Review

As of Q1 2026, Sofinnova Investments held 89 positions worth $2.63B, up 13% from $2.32B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sofinnova Investments deployed $315M of net new capital in Q1 2026, opening 29 new positions and adding to 24 existing holdings. Its largest new stake was Biogen: 229,521 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was AstraZeneca, an estimated $69.4M trimmed.

  • Sofinnova Investments's largest Q1 2026 buy was Biogen: 229,521 shares worth $42.1M.
  • Sofinnova Investments added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $69M increase.
  • Sofinnova Investments's biggest Q1 2026 reduction was AstraZeneca, cutting an estimated $69.4M.
  • Sofinnova Investments fully exited Vertex Pharmaceuticals in Q1 2026, selling an estimated $74.6M.
  • Sofinnova Investments's ten largest holdings make up 49% of its $2.63B portfolio in Q1 2026.
  • Sofinnova Investments opened 29 new positions and closed 15 in Q1 2026.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $2.63B.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.